Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the growing use of biologics to treat the disease. We expect the market to expand further over the 2019-2029 forecast period, fueled by increasing disease prevalence and the launch and growing uptake of targeted agents. Benvitimod, a topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA), is the most notable of these agents, approved by the NMPA for mild to moderate plaque psoriasis in 2019. However, despite recently launched therapies and emerging therapies set to launch in the coming years, a high unmet need for targeted agents will remain. Additionally, with the ongoing reforms in the regulatory and access and reimbursement landscape of China, multinational companies are likely to be increasingly incentivized to enter the Chinese psoriasis market.
- How large is China’s drug-treatable psoriasis population, and how will drug-treatment rate change during the forecast period?
- Which are the most commercially relevant drugs in China’s psoriasis market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the key market access considerations for key therapies in the psoriasis pipeline in China? What sales/uptake could they secure in psoriasis?
- What are the key drivers and constraints in the Chinese psoriasis market, and how will the market evolve over the forecast period?
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with dermatologists. Supported by survey data collected for this and other DRG research.
Diagnosed prevalence of psoriasis in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.
Ten-year, annualized, drug-level sales and patient shares of key psoriasis therapies through 2029, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 5+ agents; Phase II: 7+ agents; coverage of select early-phase products.
- Psoriasis|China In-Depth|China
Author(s): Amardeep Singh, M.Pharma; T.J. Arndt, MPH, CPH
Amardeep is a Senior Analyst in Decision Resources Group’s China-In-Depth team. In this role, he specializes in disease landscape and forecast reports based on a range of indications and therapy areas and focused specifically on the China healthcare market. Prior to joining Decision Resources Group, Amardeep has worked with WNS Global Services for more than 5 years, where he worked in commercial analytics team to support Respiratory franchise of one of the top ten global pharma company. He also worked with GlobalData for years and authored the syndicated reports on Rare, Ophthalmology and Psychiatric disorders. He earned a master’s degree in Pharmaceutical Management from University of Delhi and Bachelor of Pharmacy from Guru Gobind Singh Indraprastha University (GGSIPU), New Delhi.
joined Decision Resources Group in 2018 as an entry-level epidemiologist and previously worked in basic sciences research academia. earned his Masters in Public Health from the University of Florida, where he conducted an internship focused on developing a clinical model to non-invasively screen for Non-Alcoholic Steatohepatitis (NASH). He also holds a in Microbiology & Cell Science and a in Spanish, both from the University of Florida. During his undergraduate and graduate career, he worked in two physiology-based research labs at the University of Florida, focusing on maternal and fetal stresses during pregnancy and parturition.